新型四氢苯并[4',5']噻吩并[3',2'∶5,6]吡啶并[4,3-d]嘧啶类化合物衍生物的合成及抗肿瘤活性

本文以环己酮为原料,通过氮杂Wittig反应合成了一系列结构新颖的取代四氢苯并噻吩并吡啶并嘧啶衍生物,并采用MTT法考察所合成目标化合物对CNE2、KB、MGC-803、MCF-7和PC3这5种肿瘤细胞的抑制活性。初步的生物活性结果表明,目标化合物对5种肿瘤细胞均有抑制活性,尤其是对胃癌MGC-803细胞展现出了更强的抑制活性。其中3-(4-氟苯基)-2-((4-氟苯基)氨基)-5-甲基-8,9,10,11-四氢苯并[4',5']噻吩并[3',2':5,6]吡啶并[4,3-d]嘧啶-4(3H)-酮[化合物8c,IC_(50)=(0. 9±0. 25)μmol·L~(-1)]对MGC-803的活性最强,是5-氟尿嘧啶[IC_(50)=(18. 4±1. 43)μmol·L~(-1)]的20倍;同时,目标化合物对正常的胃黏膜上皮细胞GES-1没有毒性。四氢苯并[4',5']噻吩并[3',2':5,6]吡啶并[4,3-d]嘧啶类化合物具有良好的抗肿瘤活性,值得进一步深入研究。     

新型喹啉-吲哚衍生物的设计、合成及抗肿瘤活性研究（英文）

作为开发新型有效抗癌药物的进一步工作,采用分子杂交策略和路易斯酸催化偶联反应设计合成了一系列新型喹啉-吲哚类化合物.使用噻唑蓝(MTT)法评估了所合成的化合物对人胃癌细胞(MGC-803)、人食管癌细胞(Kyse450)和人结肠癌细胞(HCT-116)的体外抑制活性.其中,2-氯-4-(5-甲氧基-1H-吲哚-3-基)喹啉(9b)展示较好的体外抗肿瘤活性,对MGC-803、Kyse450和HCT-116三种人源癌细胞IC50值分别为0.58, 0.60和0.68μmol·L-1,优于阳性对照药5-氟尿嘧啶(5-Fu)对这三种肿瘤细胞的抑制活性.进一步机制研究表明,化合物9b能够剂量依赖地抑制人胃癌细胞MGC-803和HGC-27的增殖和克隆形成.化合物9b能够诱导人胃癌细胞MGC-803和HGC-27内源性凋亡和下调相关凋亡蛋白的表达,并使细胞周期阻滞在G2/M期.以上结果表明,化合物9b可以作为先导化合物,用于进一步研究开发新型高效抗肿瘤药物.     

3-芳基-7-羟基喹啉类拓扑异构酶Ⅱα抑制剂的合成及抗肿瘤活性研究

人脱氧核糖核酸(DNA)拓扑异构酶Ⅱα(topoisomerase Ⅱα, Topo Ⅱα)是重要的抗肿瘤药物靶标之一.为发现高效、低毒的Topo Ⅱα抑制剂,通过对先导化合物6-(3,4-二羟基苯基)萘酚(CS1)进行骨架跃迁,设计合成了21个3-芳基-7-羟基喹啉衍生物.采用DNA松弛实验评价体外Topo Ⅱα抑制活性,结果显示大部分化合物对Topo Ⅱα活性有抑制作用;采用人三阴乳腺癌MDA-MB-231细胞和人宫颈癌HeLa细胞生长抑制实验体外评价抗肿瘤活性,结果表明3-(2,4-二甲氧基苯基)-7-羟基喹啉(4j)对HeLa细胞有明显毒性(IC_(50)=0.8μmol·L~(-1)), 3-(4-羟基苯基)-7-羟基喹啉(4e)对MDA-MB-231(IC_(50)=1.1μmol·L~(-1))和HeLa(IC_(50)=4.2μmol·L~(-1))细胞均有明显毒性,阳性对照CS1对MDA-MB-231和HeLa细胞的IC_(50)值分别为3.8和2.5μmol·L~(-1).研究结果为设计合成新的喹啉类高效拓扑异构酶Ⅱα抑制剂提供了新思路.     

含苯并咪唑的2,4-取代喹唑啉衍生物的合成及抗肿瘤活性评价（英文）

为了寻找高效的抗肿瘤药物,设计并合成了一系列新型的2,4-取代喹唑啉类衍生物,采用噻唑蓝(MTT)法对目标化合物在人类胃癌细胞(MGC-803)、乳腺癌细胞(MCF-7)和人正常胃黏膜上皮细胞GES-1进行抗肿瘤活性评价,结果显示部分化合物对MGC-803和MCF-7表现出中度至强效的抗肿瘤活性.喹唑啉的4位被不同芳胺取代时,2-(((1H-苯并[d]咪唑-2-基)甲基)硫基)-N-(4-甲氧基苯基)喹唑啉-4-胺(15e)对MGC-803具有较好的抗肿瘤活性,IC50值为4.60μmol·L-1;喹唑啉的4位被不同查尔酮取代时,(E)-1-(4-((2-(((1H-苯并[d]咪唑-2-基)甲基)硫基)喹唑啉-4-基)氨基)苯基)-3-(3-硝基苯基)丙-2-烯-1-酮(15k)对MGC-803具有很强的抗肿瘤活性, IC50值为0.97μmol·L-1,明显优于化合物15e.但是化合物15e对GES-1的毒性远远大于化合物15k,化合物15k的毒性与对照药品5-氟尿嘧啶和吉非替尼相近.分子对接结果显示,化合物15k与表皮生长因子受体(EGFR)的结合模式优于15e,为研究新型的EGFR抑制剂提供了新的思路.     

新型吲哚-嘧啶联芳类化合物的设计、合成及抗肿瘤活性研究（英文）

设计合成了一系列新型的吲哚-嘧啶联芳类化合物,并评估了它们对组蛋白去甲基化酶(LSD1)的抑制活性和5种肿瘤细胞系(MGC-803, PC-3, EC-109, PC-12和MCF-7)的抗增殖活性.探讨了22个新型吲哚-嘧啶联芳类骨架衍生物的主要构效关系.在这些化合物中,1-(4-(4-(1-甲基-1H-吲哚-3-基)嘧啶-2-基)哌嗪-1-基)-2-((3,4,5-三甲氧基苯基)氨基)乙-1-酮(6i)展示出了潜在的LSD1抑制活性(IC_(50)=1.03μmol/L),而1-(4-(4-(1-甲基-1H-吲哚-3-基)嘧啶-2-基)哌嗪-1-基)-2-(间甲苯胺)乙-1-酮(6c),2-((4-丁基苯基)氨基)-1-(4-(4-(1-甲基-1H-吲哚-3-基)嘧啶-2-基)哌嗪-1-基)乙-1-酮(6f)和2-((3-氟苯基)氨基)-1-(4-(4-(1-甲基-1H-吲哚-3-基)嘧啶-2-基)哌嗪-1-基)乙-1-酮(6k)对PC-3细胞显示出潜在的抗肿瘤活性.其中活性最强的化合物6k的对PC-3细胞系IC_(50)值为2.75μmol/L,可作为生物活性片段和开发更有效抗肿瘤药物的靶点化合物.     

新型5位与6位取代的吲唑类衍生物的合成及抗肿瘤活性研究

为了寻找高效低毒的新型抗肿瘤药物,设计并合成了新型的5位与6位取代的吲唑类化合物.采用噻唑蓝(MTT)法对目标化合物在PC-3(人前列腺癌细胞)、MCF-7(人乳腺癌细胞)、Hep G-2(人肝癌细胞)和MGC-803(人胃癌细胞)四种人类癌细胞的抗增殖活性进行评价.结果显示大部分化合物对PC-3具有特异性的抗增殖活性.其中,N-(1-苄基-1H-1,2,3-三唑-4-基)甲基)-1-异丙基-1H-吲哚唑-5-羧酰胺(8a)和N-[(1-苄基-1H-1,2,3-三唑-4-基)甲基]-1-异丙基-1H-吲唑-6-甲酰胺(14a)对PC-3细胞的抗增殖活性较好, IC₅₀值分别为6.21和6.43μmol/L,为前列腺癌抗肿瘤药物的研究提供了思路.     

N-呋喃酮基磺酰肼的合成与抗肿瘤活性研究

以5-甲氧基-3,4-二卤-2(5H)-呋喃酮和磺酰肼为原料,DMAP为催化剂,设计合成10个N-呋喃酮基磺酰肼类化合物(4a～4j),产率在75～92%之间,并通过~1H NMR对所有目标化合物进行了结构表征。采用MTT法测定目标化合物对人乳腺癌(MCF-7)、人神经胶质瘤(U87)、人肺癌(A549)细胞的体外抑制活性,结果显示部分目标化合物表现出较好的抗肿瘤活性,其中化合物4d效果最佳,对MCF-7、U87、A549的IC_(50)值分别达到7.33±0.36μmol·L~(-1)、5.68±0.28μmol·L~(-1)和17.09±0.23μmol·L~(-1)。     

2,5-二取代吲哚衍生物的合成及抗增殖活性研究

以对硝基苯肼为起始原料,采用费舍尔吲哚合成法合成中间体5-硝基吲哚-2-羧酸酯(3),经还原合成5-氨基吲哚-2-羧酸酯(4),再与4-甲氧基-2-甲苯基异氰酸酯合成脲(5),(5)在水合肼作用下5-(3-(4-甲氧基-2-甲苯基)脲基)-1H-吲哚-2-碳酰肼(6),化合物6和取代醛反应,合成了6个2,5-二取代吲哚衍生物(7a～7f),其结构经~1HNMR,~(13)CNMR和HR-MS表征。采用MTT法研究了7a～7f对人肺癌细胞(A549)和人肝癌细胞(HepG-2)的体外抗增殖活性。结果显示:7d体外抑制活性最优,其IC_(50)分别为10.35μmol·L~(-1)、12.60μmol·L~(-1)。     

三唑类白杨素衍生物的设计、合成及其抗增殖活性研究

合成了2个系列的白杨素衍生物,采用噻唑蓝(MTT)法测试了所有化合物针对六种肿瘤细胞的体外抗增殖活性,包括MGC-803, BEL-7402, HepG2, HeLa, A549以及SGC-7901细胞.实验结果显示, 7-[1-(3-氟苯基)-1H-1,2,3-三唑-4-甲氧基]-白杨素(1c)与7-[1-(2-氯苯基)-1H-1,2,3-三唑-4-甲氧基]-白杨素(1g)针对MGC-803细胞的活性与先导化合物白杨素及阳性对照药5-氟尿嘧啶相比显著提高.因此,化合物1c与1g具有深入研究用以开发抗癌药物的潜能.     

7-O-羧烷基化白杨素衍生物的合成及其抗癌活性

以白杨素(1)为起始原料,与溴代羧酸乙酯经取代反应制得中间体7-O-乙氧羰基烷基白杨素(3a~3d);3a~3d经水解反应合成了7-O-羧烷基化的白杨素衍生物(4a~4d),其中4b~4d为新化合物,其结构经1H NMR,13C NMR,IR和ESI-MS表征。初步的体外抗癌活性实验结果表明,3和4对人肝癌细胞Hep G2和人胃癌细胞MGC-803具有一定的抗癌活性,且大多数化合物的抗癌活性比母体化合物1强,其中6-(5-羟基-2-苯基-4H-苯并吡喃酮-7-氧)己酸(4d,IC504.04μmol·L-1)对MGC-803细胞的活性抑制作用强于阳性药物DDP(IC504.40μmol·L-1)。     

Design,Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives

The chalcone and quinoline scaffolds are frequently utilized to design novel anticancer agents. As the continuation of our work on effective anticancer agents, we assumed that linking chalcone fragment to the quinoline scaffold through the principle of molecular hybridization strategy could produce novel compounds with potential anticancer activity. Therefore, quinoline-chalcone derivatives were designed and synthesized, and we explored their antiproliferative activity against MGC-803, HCT-116, and MCF-7 cells. Among these compounds, compound 12e exhibited a most excellent inhibitory potency against MGC-803, HCT-116, and MCF-7 cells with IC₅₀ values of 1.38, 5.34, and 5.21 µM, respectively. The structure–activity relationship of quinoline-chalcone derivatives was preliminarily explored in this report. Further mechanism studies suggested that compound 12e inhibited MGC-803 cells in a dose-dependent manner and the cell colony formation activity of MGC-803 cells, arrested MGC-803 cells at the G2/M phase and significantly upregulated the levels of apoptosis-related proteins (Caspase3/9 and cleaved-PARP) in MGC-803 cells. In addition, compound 12e could significantly induce ROS generation, and was dependent on ROS production to exert inhibitory effects on gastric cancer cells. Taken together, all the results suggested that directly linking chalcone fragment to the quinoline scaffold could produce novel anticancer molecules, and compound 12e might be a valuable lead compound for the development of anticancer agents.     

Synthesis and Biological Evaluation of Amino Chalcone Derivatives as Antiproliferative Agents

Chalcone is a common scaffold found in many biologically active compounds. The chalcone scaffold was also frequently utilized to design novel anticancer agents with potent biological efficacy. Aiming to continue the research of effective chalcone derivatives to treat cancers with potent anticancer activity, fourteen amino chalcone derivatives were designed and synthesized. The antiproliferative activity of amino chalcone derivatives was studied in vitro and 5-Fu as a control group. Some of the compounds showed moderate to good activity against three human cancer cells (MGC-803, HCT-116 and MCF-7 cells) and compound 13e displayed the best antiproliferative activity against MGC-803 cells, HCT-116 cells and MCF-7 cells with IC₅₀ values of 1.52 μM (MGC-803), 1.83 μM (HCT-116) and 2.54 μM (MCF-7), respectively which was more potent than the positive control (5-Fu). Further mechanism studies were explored. The results of cell colony formatting assay suggested compound 10e inhibited the colony formation of MGC-803 cells. DAPI fluorescent staining and flow cytometry assay showed compound 13e induced MGC-803 cells apoptosis. Western blotting experiment indicated compound 13e induced cell apoptosis via the extrinsic/intrinsic apoptosis pathway in MGC-803 cells. Therefore, compound 13e might be a valuable lead compound as antiproliferative agents and amino chalcone derivatives worth further effort to improve amino chalcone derivatives’ potency.     

Design,Synthesis and Anticancer Activity of New Polycyclic: Imidazole,Thiazine, Oxathiine,Pyrrolo-Quinoxaline and Thienotriazolopyrimidine Derivatives

In this article, we showed the synthesis of new polycyclic aromatic compounds, such as thienotriazolopyrimidinones, N-(thienotriazolopyrimidine) acetamide, 2-mercapto-thienotriazolo-pyrimidinones, 2-(((thieno-triazolopyrimidine) methyl) thio) thieno-triazolopyrimidines, thieno-pyrimidotriazolo-thiazines, pyrrolo-triazolo-thienopyrimidines, thienopyrimido-triazolopyrrolo-quinoxalines, thienopyrimido-triazolo-pyrrolo-oxathiino-quinoxalinones, 1,4-oxathiino-pyrrolo- triazolothienopyrimidinones, imidazopyrrolotriazolothienopyrimidines and 1,2,4-triazoloimidazo- pyrrolotriazolothienopyrimidindiones, based on the starting material 2,3-diamino-6-benzoyl-5- methylthieno[2,3-d]pyrimidin-4(3H)-one (3). The chemical structures were confirmed using many spectroscopic ways (IR, ¹H, ¹³C, −NMR and MS) and elemental analyses. A series of thiazine, imidazole, pyrrole, thienotriazolopyrimidine derivatives were synthesized and evaluated for their antiproliferative activity against four human cancer cell lines, i.e., CNE2 (nasopharyngeal), KB (oral), MCF-7 (breast) and MGC-803 (gastric) carcinoma cells. The compounds 20, 19, 17, 16 and 11 showed significant cytotoxicity against types of human cancer cell lines.     

新型N~6-哌嗪取代腺苷衍生物的合成及其抗肿瘤活性

以腺苷为母体,对其N6-位进行结构改造,首先经邻位双羟基保护,N6-位氯代,再在N6-位引入哌嗪环制得中间体2',3'-异丙叉-6-哌嗪嘌呤核苷(4);4与N-氯乙酰苯胺类似物(6a~6h)偶联后脱除邻位双羟基保护合成了8个新型的N6-哌嗪取代腺苷衍生物(8a~8h),其结构经1H NMR,13C NMR和HR-ESI-MS表征。采用MTT法研究了8a~8h对Hela肿瘤细胞的抑制活性。结果表明:大部分目标化合物对Hela肿瘤细胞具有较好的抑制活性,其中2-{4-[9-(3,4-二羟基-5-羟甲基-四氢呋喃-2-基)-9H-嘌呤-6-基]-哌嗪-1-基}-N-(3-氟苯基)-乙酰胺(8e)的活性最好,IC50为21.74μmol·L-1。     

Novel diphenylamine 2,4'-dicarboxamide based azoles as potential epidermal growth factor receptor inhibitors: synthesis and biological activity

Several hybrid molecules of diphenylamine-2,4'-dicarboxamide with various azolidinones and related heterocyclic rings have been synthesized and explored as epidermal growth factor receptor (EGFR) kinase inhibitors. Most of them displayed promising in vitro tyrosine kinase inhibition as well as potent cellular antiproliferative activity in the EGFR over-expressing breast cancer cell line (MCF-7). Compounds 12b and 13b that exhibited the highest inhibition in the kinase assay (89, 81% inhibition at 10 μM, respectively), showed potent antiproliferative effect against MCF-7 tumor cell line (IC(50) 1.04, 0.91 μM respectively). Molecular docking studies revealed that these compounds can bind to ATP binding site of the EGFR kinase domain and were involved in H-bonding with Met 793, in analogy to the known EGFR tyrosine kinase inhibitors. Moreover, compounds 15a-c possessed profound antitumor activity (IC(50) 0.59-0.73 μM) and significant EGFR-TK inhibition, making them of particular interest. In summary, the newly synthesized compounds provide promising new lead for the future design and development of anticancer agents of potential EGFR-TK inhibitory activity.     

伊马替尼衍生物的合成及其抗肿瘤活性

以4-硝基-2-氨基甲苯为起始原料,经加成、缩合、环化和还原反应制得中间体N-(2-甲基-5-氨基苯基)-4-(3-吡啶基)嘧啶-2-胺(4),再与取代酰氯反应,合成了7个新型伊马替尼衍生物（5a~5g）,其结构经¹H NMR, ¹³C NMR和HR-MS 表征。采用四甲基偶氮唑盐(MTT)法考察了5对人肝癌细胞(HepG₂)、子宫颈癌细胞（Hela）、肺癌细胞（H460）和乳腺癌细胞（MCF-7）体外抑制活性。结果显示：5e体外抑制活性最优,其IC₅₀分别为10.90±1.00 μmol·L^-1; 8.51±0.90 μmol·L^-1; 13.15±1.11 μmol·L^-1; 14.75±0.78 μmol·L^-1。     

Synthesis and antitumor activity of α-aminophosphonate derivatives containing thieno[2,3-d]pyrimidines

Two series of thieno[2,3-d]pyrimidine derivatives were designed and synthesized, in which bioactive a-aminophosphonate subunits were introduced at the N3 position through an N–N bond connection.The in vitro cytotoxic activity of the novel compounds was tested against human esophageal carcinoma cells(EC109), human hepatocarcinoma cells(Hep G2), human gastric carcinoma cells(MGC-803),respectively, by the MTT method. The evaluation results revealed that compounds 6mb, 6mf, 6mg, 6nd and 6nh exerted the most potent inhibition against Hep G2, MGC-803 and EC109 cells, respectively. In particular, compound 6mg presented excellent inhibitory effect against Hep G2(91.2%) and MGC-803(94.4%) cells.     

新型丁烯内酯衍生物的设计合成及诱导胃癌细胞凋亡研究

开发了一条合成天然产物Uncinine的新方法,基于此设计合成了一系列新型的丁烯内酯衍生物.通过噻唑蓝(MTT)法评价了目标化合物对胃癌细胞的增殖抑制活性,分析了其构效关系.其中,3-吗啉甲基-4-(4-叔丁基苯基)亚基丁烯内酯(9l)对MGC803的IC50为2.9μmol/L,对胃癌细胞MGC803、HGC27以及SGC7901具有明显的选择性增殖抑制作用,而对正常的胃粘膜上皮细胞GES1具有较小的毒性.初步的作用机制研究表明,化合物9l诱导胃癌细胞MGC803凋亡依赖Caspase 9/3激活.